|

An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2025-06-24
Est. completion2027-06-30
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted

Summary

Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Female patients aged ≥ 18 years old;
2. Signed ICF, including consent for archival FFPE tumor tissue block testing;
3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
5. The presence of biopsy or postoperative archival FFPE tumor sample (block);
6. Availability of source medical documentation.

Exclusion Criteria:

1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.

Conditions2

CancerEndometrial Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.